CAJ | 학술논문

目的观察恩替卡韦治疗慢性乙型肝炎初治患者3年的疗效.方法 82例慢性乙型肝炎初治患者,口服恩替卡韦0.5 mg,每日1次,观察治疗前后血清ALT和HBV DNA水平及治疗1、2、3年ALT复常率、HBV DNA阴转率、HBeAg消失率、HBeAg血清学转换率.结果 82例患者治疗1、2、3年时ALT复常率分别为79.3％ (65/82)、84.2％ (69/82)、92.7％ (76/82);血清HBV DNA载量分别为(3.108±1.394)、(2.637±0.571)、(2.670±0.982) log10拷贝/ml;HBV DNA阴转率分别为65.9％ (54/82)、81.7％ (67/82)、89.0％(73/82).其中60例HBeAg阳性患者治疗1、2、3年时HBeAg消失率分别为18.3％ (11/60)、43.3％(26/60)、41.7％ (25/60);血清学转换率分别为16.7％(10/60)、28.3％ (17/60)、31.7％ (19/60).结论恩替卡韦初始治疗慢性乙型肝炎患者,能有效抑制HBV DNA复制,促进ALT复常,促使HBeAg血清学转换.延长疗程,可增加HBV DNA阴转、HBeAg消失和血清学转换.
목적 관찰은체잡위치료만성을형간염초치환자3년적료효.방법 82례만성을형간염초치환자,구복은체잡위0.5 mg,매일1차,관찰치료전후혈청ALT화HBV DNA수평급치료1、2、3년ALT복상솔、HBV DNA음전솔、HBeAg소실솔、HBeAg혈청학전환솔.결과 82례환자치료1、2、3년시ALT복상솔분별위79.3％ (65/82)、84.2％ (69/82)、92.7％ (76/82);혈청HBV DNA재량분별위(3.108±1.394)、(2.637±0.571)、(2.670±0.982) log10고패/ml;HBV DNA음전솔분별위65.9％ (54/82)、81.7％ (67/82)、89.0％(73/82).기중60례HBeAg양성환자치료1、2、3년시HBeAg소실솔분별위18.3％ (11/60)、43.3％(26/60)、41.7％ (25/60);혈청학전환솔분별위16.7％(10/60)、28.3％ (17/60)、31.7％ (19/60).결론 은체잡위초시치료만성을형간염환자,능유효억제HBV DNA복제,촉진ALT복상,촉사HBeAg혈청학전환.연장료정,가증가HBV DNA음전、HBeAg소실화혈청학전환.
Objective To explore the efficacy of 3 years of continuous entecavir treatment in nucleos(t) ide-naive chronic hepatitis B patients.Methods A total of 82 chronic hepatitis B patients received the antiviral therapy of entecavir 0.5 mg/d.The ALT level and HBV-DNA loads before and after the treatment were observed.And the rates of ALT normalization,HBV DNA clearances,HBeAg loss and HBeAg seroconversion during the end of the therapy of year 1,2 and 3 were also studied.Results For the 82 patients,during the end of the therapy of year 1,2 and 3,the rates of ALT normalization were 79.3％ (65/82),84.2％ (69/82)and 92.7％ (76/82) ; the HBV-DNA loads were (3.108 ± 1.394),(2.637 ± 0.571) and (2.670 ± 0.982) log10 copies/ml; the rates of HBV DNA clearances were 65.9％ (54/82),81.7％ (67/82) and 89.0％ (73/82) respectively.And for the 60 cases of HBeAg positive patients,during the end of the therapy of year 1,2 and 3,the rates of HBeAg loss were 18.3％ (11/60),43.3％ (26/60) and 41.7％ (25/60) ; the rates of HBeAg seroconversion were 16.7％ (10/60),28.3％ (17/60) and 31.7％ (19/60) respectively.Conclusions Continuous entecavir treatment in nucleos(t) ide-naive chronic hepatitis B patients could inhibit HBV replication effectively,enhance ALT normalization and HBeAg seroconversion.And prolongationg of treatment may increase the rates of HBV DNA clearances,HBeAg loss and HBeAg seroconversion.